Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research

Immortalized cell lines are widely used in vitro tools in oncology and hematology research. While these cell lines represent artificial systems and may accumulate genetic aberrations with each passage, they are still considered valuable models for pilot, preliminary, and screening studies. Despite their limitations, cell lines are cost-effective and provide repeatable and comparable results. Choosing the appropriate cell line for acute myeloid leukemia (AML) research is crucial for obtaining reliable and relevant results. Several factors should be considered when selecting a cell line for AML research, such as specific markers and genetic abnormalities associated with different subtypes of AML. It is also essential to evaluate the karyotype and mutational profile of the cell line, as these can influence the behavior and response to the treatment of the cells. In this review, we evaluate immortalized AML cell lines and discuss the issues surrounding them concerning the revised World Health Organization and the French–American–British classifications.

• Publication year

  2023

• Venue

  International Journal of Molecular Sciences

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms24065377PMID 36982453PMCID 10049680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pan-cancer proteomic map of 949 human cell lines

  2022cited by this paper
• Antioxidant and Anti-Inflammatory Effects of Thyme (Thymus vulgaris L.) Essential Oils Prepared at Different Plant Phenophases on Pseudomonas aeruginosa LPS-Activated THP-1 Macrophages

  2022influential reference
• DSMZCellDive: Diving into high-throughput cell line data

  2022cited by this paper
• Explainable artificial intelligence for precision medicine in acute myeloid leukemia

  2022cited by this paper
• Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure

  2022cited by this paper
• Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

  2022cited by this paper
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

  2022influential reference
• Structure-activity relationships reveal a 2-furoyloxychalcone as a potent cytotoxic and apoptosis inducer for human U-937 and HL-60 leukaemia cells.

  2022cited by this paper
• JMJD1C Regulates Megakaryopoiesis in In Vitro Models through the Actin Network

  2022cited by this paper
• AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.

  2022cited by this paper
• Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern

  2022cited by this paper
• NKL Homeobox Genes NKX2-3 and NKX2-4 Deregulate Megakaryocytic-Erythroid Cell Differentiation in AML

  2021cited by this paper
• Discovery of Sulforaphane as an Inducer of Ferroptosis in U-937 Leukemia Cells: Expanding Its Anticancer Potential

  2021cited by this paper
• Betulinic Acid–Doxorubicin-Drug Combination Induced Apoptotic Death via ROS Stimulation in a Relapsed AML MOLM-13 Cell Model

  2021cited by this paper
• Circular RNA circCRKL inhibits the proliferation of acute myeloid leukemia cells via the miR-196a-5p/miR-196b-5p/p27 axis

  2021cited by this paper
• LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia

  2021cited by this paper
• Incomptine A Induces Apoptosis, ROS Production and a Differential Protein Expression on Non-Hodgkin’s Lymphoma Cells

  2021cited by this paper
• Genetic Expression Screening of Arsenic Trioxide-Induced Cytotoxicity in KG-1a Cells Based on Bioinformatics Technology

  2021cited by this paper
• EVI1 dysregulation: impact on biology and therapy of myeloid malignancies

  2021cited by this paper
• Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway

  2020cited by this paper
• NPM1-mutated acute myeloid leukemia: from bench to bedside.

  2020cited by this paper
• Low frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia

  2020influential reference
• Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations

  2020cited by this paper
• Reactive Oxygen Species Imaging in U937 Cells

  2020influential reference
• EVI1 in Leukemia and Solid Tumors

  2020cited by this paper
• JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.

  2020cited by this paper
• FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.

  2020cited by this paper
• Acute myeloid leukemia with minimal differentiation

  2020influential reference
• Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations

  2020influential reference
• Toxicity of pesticides toward human immune cells U-937 and HL-60

  2020cited by this paper
• Selectivity of T Cell Engager AMV564 Against Different Leukemic Blast Populations and Potential Application for Patient Selection

  2020cited by this paper
• Establishment of a megakaryoblastic cell line for conventional assessment of platelet calcium signaling

  2020cited by this paper
• Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.

  2019cited by this paper
• t(6;8)(p21;q24) MYC/SUPT3H

  2019cited by this paper
• Classification of acute myeloid leukemia

  2019cited by this paper
• The LL-100 panel: 100 cell lines for blood cancer studies

  2019cited by this paper
• Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia

  2019cited by this paper
• Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression.

  2019cited by this paper
• Curcumin induces apoptosis in JAK2‐mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways

  2019cited by this paper
• Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia

  2019cited by this paper
• National Center for Biotechnology Information

  2019cited by this paper
• Acute myeloid leukemia with minimal differentiation (AML M0) mimicking acute lymphoblastic leukemia

  2018influential reference
• A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report

  2018cited by this paper
• Molecular Characterization of Human Leukemia 60 (HL-60) Cells as a Model of Acute Myelogenous Leukemia Post Cryopreservation.

  2018cited by this paper
• p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction

  2018cited by this paper
• Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome

  2018cited by this paper
• An immortalised mesenchymal stem cell line maintains mechano-responsive behaviour and can be used as a reporter of substrate stiffness

  2018cited by this paper
• Abstract 1890: Inecalcitol respectively induces or increases CD38 expression at the surface of CD38-or CD38+AML cell lines representative of all 9 FAB subtypes except M6

  2018cited by this paper
• Clinical diagnosis of adult patients with acute megakaryocytic leukemia

  2018cited by this paper
• The Cellosaurus, a Cell-Line Knowledge Resource.

  2018cited by this paper
• Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodeling

  2018cited by this paper
• Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

  2017cited by this paper
• Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes

  2017cited by this paper
• Genomic landscape of human erythroleukemia K562 cell line, as determined by next-generation sequencing and cytogenetics

  2017cited by this paper
• A map of gene expression in neutrophil-like cell lines

  2017cited by this paper
• Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

  2017cited by this paper
• Acute Myeloid Leukemia—Genetic Alterations and Their Clinical Prognosis

  2017cited by this paper
• Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia

  2017cited by this paper
• THP-1 cells as a model for human monocytes.

  2016influential reference
• Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing

  2016cited by this paper
• SIRT1 is a critical regulator of K562 cell growth, survival, and differentiation.

  2016cited by this paper
• Acute megakaryocytic leukemia: What have we learned.

  2016cited by this paper
• The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses

  2016influential reference
• Morphology of leukaemias

  2016cited by this paper
• Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).

  2016cited by this paper
• Effect of active fraction of Eriocaulon sieboldianum on human leukemia K562 cells via proliferation inhibition, cell cycle arrest and apoptosis induction.

  2016cited by this paper
• DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation

  2016cited by this paper
• Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids

  2016cited by this paper
• NCI-H716 Cells -- The Impact of Food Bioactives on Health: in vitro and ex vivo models

  2015cited by this paper
• The Impact of Food Bioactives on Health

  2015cited by this paper
• Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression

  2015cited by this paper
• ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A

  2015cited by this paper
• NRF2 Signaling Negatively Regulates Phorbol-12-Myristate-13-Acetate (PMA)-Induced Differentiation of Human Monocytic U937 Cells into Pro-Inflammatory Macrophages

  2015cited by this paper
• MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition

  2015cited by this paper
• Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies

  2014cited by this paper
• DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.

  2014cited by this paper
• A review of AML classification: a single institution experience in a developing country

  2014cited by this paper
• Severe disruption of the cytoskeleton and immunologically relevant surface molecules in a human macrophageal cell line in microgravity-Results of an in vitro experiment on board of the Shenzhou-8 space mission

  2014cited by this paper
• Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

  2014cited by this paper
• THP-1 cell line: an in vitro cell model for immune modulation approach.

  2014cited by this paper
• DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy

  2014cited by this paper
• Abstract 90: Development of a systemic Kasumi-3 acute myeloid leukemia model in NSG mice

  2014cited by this paper
• U937 variant cells as a model of apoptosis without cell disintegration

  2013cited by this paper
• 21 – Acute Myeloid Leukemia, Not Otherwise Specified

  2013cited by this paper
• Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1.

  2013cited by this paper
• The landscape of somatic mutations in Down syndrome–related myeloid disorders

  2013cited by this paper
• Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

  2013cited by this paper
• RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction

  2013cited by this paper
• Impact of oxLDL and LPS on C-type Natriuretic Peptide System is Different between THP-1 Cells and Human Peripheral Blood Monocytic Cells

  2012cited by this paper
• RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group

  2012cited by this paper
• The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations

  2012cited by this paper
• Stimulation of lysozyme release by selected microbial preparations.

  2012cited by this paper
• The role of the GATA2 transcription factor in normal and malignant hematopoiesis.

  2012cited by this paper
• Gallic Acid Inhibits Cell Viability and Induces Apoptosis in Human Monocytic Cell Line U937

  2011cited by this paper
• Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

  2011cited by this paper
• Agaritine from Agaricus blazei Murrill induces apoptosis in the leukemic cell line U937.

  2011cited by this paper
• JAK2 inhibitors: are they the solution?

  2011cited by this paper
• Proteomic differentiation pattern in the U937 cell line.

  2011cited by this paper
• Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663

  2011cited by this paper
• p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

  2011cited by this paper

• A human pathophysiological 3D-bone marrow model reveals immune and stromal cell heterogeneity

  2026cites this paper
• Isolation and Characterization of 5-(1-Hydroxyethyl)-Dihydro-2-Furanone from Angiopteris evecta with Potent Anti-Inflammatory and Anti-Leukemic Activities

  2026cites this paper
• Therapeutic Potential of Ginger Rhizomes (Zingiber officinale) on Leukemia.

  2026cites this paper
• First-in-Class Dual PDGFR/Carbonic Anhydrase IX/XII Inhibitors: 6,7-Dimethoxyquinoline-Sulfonamides as Promising Antileukemic Agents.

  2026cites this paper
• Cell Lines in Myelodysplastic Syndromes/Neoplasms (MDS) Research: A Review of Existing Models and Their Applications

  2026cites this paper
• Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions

  2026cites this paper
• Synthesis, antimicrobial, cytotoxic and in silico studies of pyridine-quinazolin-4(3H)-one hybrids

  2025cites this paper
• A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug Resistance

  2025cites this paper
• Acute Myeloid Leukemia‐Osteoblast Interaction Mediated Autophagy Induction Protects Against Cytarabine Induced Apoptosis

  2025cites this paper
• Multiplexed Lectin-PAINT super-resolution microscopy enables cell glycotyping

  2025cites this paper
• Non-Invasive Leukemia Detection via CSRR Sensor

  2025cites this paper
• Evaluating feature extraction in ovarian cancer cell line co-cultures using deep neural networks

  2025cites this paper
• Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia

  2025influential citation
• Transcriptomic characterisation of acute myeloid leukemia cell lines bearing the same t(9;11) driver mutation reveals different molecular signatures

  2025cites this paper
• The dual effect of interferon-γ in acute myeloid leukemia: A narrative review.

  2025cites this paper
• CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models

  2025cites this paper
• Phosphatidylglucoside regulates apoptosis of human neutrophilic lineage cells

  2025cites this paper
• Outcomes of patients with Acute Myeloid Leukemia receiving venetoclax in combination with azacitidine: A single center retrospective study from Pakistan

  2025cites this paper
• MARCH1, transcriptionally regulated by POU2F2, facilitates acute myeloid leukemia progression via inducing MYCT1 degradation

  2025cites this paper
• DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT

  2025cites this paper
• From genotype to phenotype: decoding mutations in blasts by holo-tomographic flow cytometry

  2025cites this paper
• Enlarged PML-nuclear bodies trigger conflicting cell cycle signal-mediated cytotoxicity in leukemia cells

  2025cites this paper
• SKP2 regulates TERT independently of RUNX1/ETO in AML subtypes lacking the t(8,21) translocation via CDKN1B and RB phosphorylation states

  2025cites this paper
• Extracellular Vesicles Profiling in Acute Myeloid Leukemia Cell Lines: A Proteomic Characterization

  2025cites this paper
• Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia

  2025cites this paper
• Understanding the Role of All-Trans Retinoic Acid in Acute Myeloid Leukemia Cells

  2025cites this paper
• Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy

  2025cites this paper
• CHARACTERISTICS OF LIVER DYSFUNCTION AT THE ONSET OF ACUTE MYELOID LEUKEMIA

  2025cites this paper
• Tumor-Infiltration Mimicking Model of Contaminated Ovarian Tissue as an Innovative Platform for Advanced Cancer Research

  2024cites this paper
• N-Phenyl ureidobenzenesulfonates, a novel class of human dihydroorotate dehydrogenase inhibitors inducing differentiation and apoptosis in acute myeloid leukemia cells.

  2024cites this paper
• Antisense oligonucleotides as a targeted therapeutic approach in model of acute myeloid leukemia

  2024cites this paper
• Rapamycin and Niacin combination induces apoptosis and cell cycle arrest through autophagy activation on acute myeloid leukemia cells

  2024cites this paper
• Nanotechnology based approaches for leukemia therapy

  2024cites this paper
• Enhancer mutations modulate the severity of chemotherapy-induced myelosuppression

  2024cites this paper
• Holotrichones A and B, potent anti-leukemic lindenane-type sesquiterpene trimers with unprecedented complex carbon skeletons from a rare Chloranthus species

  2024cites this paper
• Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells

  2024cites this paper
• MicroRNA‑223 overexpression suppresses protein kinase C ε expression in human leukemia stem cell‑like KG‑1a cells

  2024cites this paper
• Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI‐503 against MLL::AF9‐driven acute myeloid leukaemia

  2024cites this paper
• A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes

  2024cites this paper
• Automated workflow for the cell cycle analysis of (non-)adherent cells using a machine learning approach

  2024cites this paper
• Are we ready to integrate 3D culture systems in acute myeloid leukemia and bone marrow microenvironment research?

  2024cites this paper
• A novel bioprinted microtumour model for studying acute-leukemia-cell- contaminated in ovarian tissue.

  2024cites this paper
• Differentiating leukemia subtypes based on metabolic signatures using hyperpolarized 13C NMR

  2024cites this paper
• In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia

  2024cites this paper
• Genomic discovery of EF-24 targets unveils antitumorigenic mechanisms in leukemia cells

  2024cites this paper
• A novel in-vitro model of the bone marrow microenvironment in AML identifies CD44 and Focal Adhesion Kinase as therapeutic targets to reverse cell adhesion-mediated drug resistance

  2024cites this paper
• The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9

  2024cites this paper
• Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia

  2024cites this paper
• Assessment of some Biochemical Markers as risk factors in Egyptian children affected with Acute Lymphoblastic Leukemia

  2023cites this paper
• An alternative NURF complex sustains acute myeloid leukemia by regulating the accessibility of insulator regions

  2023cites this paper
• Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy

  2023cites this paper
• The antitumor effects of WNT5A against hematological malignancies

  2023cites this paper
• Analisis Segmentasi Leukosit pada Acute Myeloid Leukemia dengan Active Contour Without Edge dan Watershed Distance Transform

  2023cites this paper
• The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients

  2023cites this paper
• Identification of novel theraputic opportunities in FLT3-mutated AML cell lines and an investigation of the biology behind the resistance

  year unknowninfluential citation